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FIGURE 3
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DUAL TARGETING OF MIR-208 AND MIR-499
IN THE TREATMENT OF CARDIAC
DISORDERS
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a national stage application of Interna-
tional Application No. PCT/US2010/023234, filed Feb. 4,
2010, which claims the benefit of U.S. Provisional Applica-
tion No. 61/149,915, filed Feb. 4, 2009, both of whichis are
herein incorporated by reference in their entireties.
STATEMENT OF GOVERNMENT SUPPORT
This invention was made with government support under
Grant Number HL53351-06 awarded by the National Insti-
tutes of Health. The government has certain rights in the
invention.
DESCRIPTION OF THE TEXT FILE SUBMITTED
ELECTRONICALLY
The contents of the text file submitted electronically here-
with are incorporated herein by reference in their entirety: A
computer readable format copy ofthe Sequence Listing(file-
name: MIRG_013__01WO_SeqList_ST25 txt, date
recorded: Feb. 1, 2010,file size 5 kilobytes).
FIELD OF THE INVENTION
The present invention relates to the treatment of cardiac
and musculoskeletal disorders by administering agents that
modulate the activity or expression of microRNAs (miR-
NAs). In particular, the invention provides a methodfortreat-
ing or preventing cardiac disorders by inhibiting the expres-
sion or activity of both miR-208a/miR-208b and miR-499 in
the heart cells ofa subject, including humans.In addition, the
invention provides a methodfor treating or preventing mus-
culoskeletal disorders by increasing the expression oractivity
of both miR-208b and miR-499 in skeletal muscle cells of a
subject.
BACKGROUND OF THE INVENTION
Heart disease and its manifestations, including coronary
artery disease, myocardial infarction, congestive heart failure
and cardiac hypertrophy, clearly present a major health risk in
the United States today. The cost to diagnose, treat and sup-
port patients suffering from these diseases is well into the
billions of dollars. Two particularly severe manifestations of
heart disease are myocardial infarction and cardiac hypertro-
phy.
Myocardial infarction, commonly knownasa heart attack,
is caused by a sudden andsustained lack ofblood flow to the
heart tissue, which is usually the result of a narrowing or
occlusion of a coronary artery. Without adequate blood sup-
ply, the tissue becomes ischemic, leading to the death of
cardiomyocytes (e.g. heart muscle cells) and vascular struc-
tures. The necrotic tissue resulting from the death of the
cardiomyocytes is generally replaced by scartissue, which is
not contractile, fails to contribute to cardiac function, and
often plays a detrimental role in heart function by expanding
during cardiac contraction, or by increasing the size and
effective radius of the ventricle, for example, becoming
hypertrophic.
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Cardiac hypertrophyis an adaptive responseofthe heart to
virtually all forms of cardiac disease, including those arising
from hypertension, mechanical load, myocardial infarction,
cardiac arrhythmias, endocrine disorders, and genetic muta-
tions in cardiac contractile protein genes. While the hyper-
trophic responseis initially a compensatory mechanism that
augments cardiac output, sustained hypertrophy can lead to
dilated cardiomyopathy (DCM), heart failure, and sudden
death. In the United States, approximately half a million
individuals are diagnosed with heart failure each year, with a
mortality rate approaching 50%.
Numerous signaling pathways, especially those involving
aberrant calcium signaling, drive cardiac hypertrophy and
pathological remodeling (Heineke & Molkentin, 2006).
Hypertrophic growth in responseto stress involves different
signaling pathways and gene expression patterns than physi-
ological hypertrophy, which occurs in response to exercise.
Stress-mediated myocardial hypertrophy is a complex phe-
nomenon associated with numerous adverse consequences
with distinct molecular and histological characteristics caus-
ing the heart to fibrose, dilate and decompensate which,
through cardiomyocyte degeneration and death, often culmi-
nates in heart failure. As such, there has been intenseinterest
in deciphering the underlying molecular mechanisms and in
discovering novel therapeutic targets for suppressing adverse
cardiac growth and ultimately failure. Understanding these
mechanismsis essential to the design ofnew therapiesto treat
cardiac hypertrophy andheart failure.
MicroRNAshaverecently been implicated in a numberof
biological processes including regulation of developmental
timing, apoptosis, fat metabolism, and hematopoietic cell
differentiation among others. MicroRNAs (miRNAs) are
small, non-protein coding RNAs of about 18 to about 25
nucleotides in length that are derived from individual miRNA
genes, from introns of protein coding genes, or from poly-
cistronic transcripts that often encode multiple, closely
related miRNAs. See review by Carrington et al. (Science,
Vol. 301(5631):336-338, 2003). MiRNAsact as repressors of
target mRNAs by promoting their degradation, when their
sequences are perfectly complementary, or by inhibiting
translation, when their sequences contain mismatches.
MiRNAsare transcribed by RNA polymeraseII (pol II) or
RNA polymeraseIII (pol ITI; see Qi et al. (2006) Cellular &
Molecular Immunology, Vol. 3:411-419) and arise from ini-
tial transcripts, termed primary miRNAtranscripts (pri-miR-
NAs), that are generally several thousand bases long. Pri-
miRNAsare processed in the nucleus by the RNase Drosha
into about 70- to about 100-nucleotide hairpin-shaped pre-
cursors (pre-miRNAs). Following transport to the cytoplasm,
the hairpin pre-miRNAis further processed by Dicer to pro-
duce a double-strandedmiRNA. The mature miRNAstrandis
then incorporated into the RNA-induced silencing complex
(RISC), where it associates with its target mRNAs by base-
pair complementarity. In the relatively rare cases in which a
miRNA base pairs perfectly with an mRNAtarget, it pro-
motes mRNA degradation. More commonly, miRNAs form
imperfect heteroduplexes with target mRNAs, affecting
either mRNAstability or inhibiting mRNAtranslation.
Recently, the inventors reported a_ cardiac-specific
microRNA, miR-208a, which is encodedby an intron of the
a-myosin heavy chain (MHC) gene, andis required for up-
regulation of B-MHCexpression in responseto cardiac stress
and for repression of fast skeletal muscle genes in the heart
(van Roojj et al., (2007) Science, Vol. 316: 575-579). The
present invention expands on this discovery and provides a
novel therapeutic approach to the treatment of cardiac and
musculoskeletal disorders.
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SUMMARYOF THE INVENTION
The present invention is based, in part, on the discovery
that systematic downregulation of both miR-208a and miR-
499 in heart cells produces a synergistic effect on the devel-
opment of cardiac hypertrophy, enhanced contractility, and
pathological cardiac remodeling in response to stress. The
inventors have surprisingly found that the time period for
regulating expression of stress-related genes, such as
B-MHC,is dramatically decreased by downregulating both
miR-208a and miR-499 byeither simultaneous or sequential
administration of miR-208a and miR-499 inhibitors. Such
dual targeting produces immediate effects on stress-related
gene expression as compared to the several month delay
required to observe similar effects with downregulation of
miR-208a alone. Accordingly,the present invention provides
a novel therapeutic approach for the treatment of pathologic
cardiac hypertrophy,heart failure, and myocardial infarction
in a subject in need thereof, including a human.
In one embodiment, the method comprises administering
an inhibitor of miR-208a or miR-208b and an inhibitor of
miR-499 to a subject, wherein the expression or activity of
miR-208a or miR-208b and miR-499 is reduced in the heart
cells of the subject following administration. In some
embodiments, the expression or activity ofmiR-208a ormiR-
208b and miR-499is reducedby greater than 60 percentin the
heart cells of the subject following administration of the
inhibitors. The miR-208 and miR-499 inhibitors include
antagomirs or antisense oligonucleotides. In one embodi-
ment, the miRNA inhibitors are encoded on a expression
vector.
In another embodiment, the cardiac stress response is
reduced in the subject following administration of an inhibi-
tor of miR-208a or miR-208b and an inhibitor of miR-499.
The cardiac stress response includes hypertrophy of cardi-
omyocytes, fibrosis of the heart, reduced expression of
a-MHC,and/or increased expression of B-MHCin the heart
cells of said subject. In certain embodiments, the reduction of
the cardiac stress response occurs less than two monthsafter
administration of the miR-208a/miR-208b and miR-499
inhibitors. In a preferred embodiment, the reduction of the
cardiac stress response occurs less than one week after
administration of the inhibitors.
In some embodiments, the miR-208a/miR-208b inhibitor
and the miR-499 inhibitor are administered sequentially.
Administration of the two inhibitors can be separated by an
interval that can be on the order of minutes to weeks. In one
embodiment, the miR-208a/miR-208b inhibitor and the miR-
499 inhibitor are administered at least 24 hours apart. In
another embodiment, the miR-208a/miR-208b inhibitor and
the miR-499 inhibitor are co-administered. The two inhibi-
tors can be administered each at a dosage of about 1 mg/kg to
about 200 mg/kg.
Thepresent invention also provides a methodoftreating or
preventing a musculoskeletal disorder in a subject in need
thereof comprising administering an agonist ofmiR-208 and
an agonist ofmiR-499 to the subject, wherein the expression
or activity of miR-208 and miR-499is increasedin the skel-
etal muscle cells of the subject following administration. In
one embodiment, the method comprises administering an
agonist of miR-208b and an agonist of miR-499 to the sub-
ject. The miRNA agonists can be polynucleotides encoding
mature miR-208a, miR-208b, or miR-499 sequences. In
some embodiments, such polynucleotides are operably
linked to a promoter sequence and provided to the subject’s
cells in an expression vector.
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The miRNAagonists may be co-administered or adminis-
tered sequentially separated by a particular time interval. In
some embodiments, the expression of one or more fast skel-
etal muscle genes in the skeletal muscle cells of a subjectis
reduced following administration of the miR-499 and miR-
208a or miR-208b agonists to the subject. One or more fast
skeletal muscle genes can include troponin 12, troponin T3,
fast skeletal myosin light chain, and alpha skeletal actin.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. MiR-208 knockout animals exhibit less cardiac
hypertrophy andfibrosis in response to thoracic aortic band-
ing. A. Schematic illustrating the thoracic aortic banding
(TAB) procedure (left). Histological sections of hearts of
wild-type and miR-208-/- mice stained for Masson
trichrome after TAB procedure or sham procedure (right).
The absence ofmiR-208 diminishes hypertrophy andfibrosis
seen in wild-type mice subjected to TAB for 21 days. B.
Relative expression levels for beta-myosin heavy chain
(B-MHC), atrial natriuretic factor (ANF), and brain natri-
uretic peptide (BNP)in hearts of wild-type and miR-208-/-
animals after a sham or TAB procedure. C. Western analysis
of a-MHC and B-MHCprotein levels in hearts of wild-type
and miR-208-/- animals after a sham or TAB procedure.
GAPDHwasdetected as a loading control.
FIG. 2. Longterm knockdown ofmiR-208 phenocopies the
inhibition of the stress response in the miR-208 knockout
animals. A. Sequence of a synthetic oligonucleotide targeted
to the mature miR-208 sequence (SEQ ID NO: 16). The
mismatch control sequence contains four base mismatches
comparedto the anti miR-208 sequence (SEQ ID NO: 17). B.
Realtime PCRanalysis showsefficient knockdown of miR-
208 in hearts of animals treated with the anti-miR-208 oligo-
nucleotide. C. Relative expression levels for beta-myosin
heavy chain (6-MHC), atrial natriuretic factor (ANF), and
brain natriuretic peptide (BNP) in hearts of animals that
received an anti-miR-208 oligonucleotide (anti 208) or a mis-
matched control (mm) after a sham or thoracic aortic banding
(TAB)procedure. While the stress markersANF and BNPare
induced in response to TAB,the animals that received anti-
miR-208 showed a decreased induction of BMHCexpression.
FIG. 3. Myh7b and miR-499 are regulated by miR-208.
Northern blot showing expression of miR-499 in hearts of
wild-type (+/+), miR-208 heterozygotes (+/—) and miR-208
knockout (-/-) mice. There is a direct correlation between the
expression of miR-208 and miR-499, as well as Myh7b in
wild-type and mutant mice. The expression of GAPDH was
measuredas a control.
FIG. 4. Myh7b and miR-499 are expressed in cardiac and
slow skeletal muscle. A. Northern analysis indicates that
miR-499 is expressed in heart and slow skeletal muscle (e.g.
soleus). RT-PCR for Myh7b shows that miR-499 is co-ex-
pressed with its hostgene. B. Real-time PCR analysis for
miR-499 on heart and four skeletal muscle types (gastrocne-
mius/plantaris (GP), tibialis anterior (TA), extensor digi-
torum longus (EDL), and soleus) confirms that miR-499 is
predominantly expressedin the heart and soleus. Only minor
levels ofmiR-499 expression can be detected in TA and EDL.
C.In situ hybridization indicates that during embryogenesis,
Myh7bis specifically expressed in the heart and somites.
FIG. 5. MiR-499 does not affect myosin expression. A.
RT-PCR analysis for Myh7b showsthat genetic deletion of
miR-499 does not affect the expression of its hostgene,
Myh7b. GP-gastrocnemius/plantaris; TA-tibialis anterior;
EDL-extensor digitorum longus. Expression ofGAPDH was
measured as a control. B. Western blot analysis ofhearts from
US 8,629,119 B2
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wild-type (WT), heterozygote (+/-), and miR-499 knockout
(KO)animals for both a- and B-MHCshowsthat deletion of
miR-499 does not affect the expression of either gene at the
protein level. C. Propylthiouracil (PTU), which blocks thy-
roid hormone biogenesis andis a strong inducer of B-MHC,
produces a decrease in a-MHCand an increase in B-MHCin
both wildtype (WT) and miR-499 knockout (KO) animals.
FIG.6. The regulation of miR-499 by in vivo knockdown
of miR-208. A. Northern analysis of miR-208 and miR-499
expression three days after tail vein injection of the indicated
amount of anti-miR-208 oligonucleotide or saline (Sal). B.
Northern analysis for miR-208 and miR-499 expression of
cardiac tissue of animals injected with either a single 80
mg/kg dose of anti-miR-208, 2x80 mg/kg doses of anti-miR-
208 on two consecutive days, or a mismatched controloligo-
nucleotide (mm) two months after treatment. C. Realtime
PCR analysis for miR-208, miR-499, miR-208b, a-MHC,
Myh7b, and B-MHCexpressionin cardiac tissue two months
after treatment with a single dose of anti-miR-208, two doses
of anti-miR-208 on two consecutive days, or two doses of a
mismatched oligonucleotide on two consecutive days. D.
Western blot analysis of B-MHC expression in cardiac tissue
two monthsafter anti-miR-208 (single 80 mg/kg dose or two
consecutive 80 mg/kg doses) or mismatch (mm) control treat-
ment.
FIG.7. Dual Targeting ofmiR-208 and miR-499. A. North-
ern analysis for miR-208, miR-208b and miR-499 in cardiac
tissue of wild-type and miR-499 knockout animals shows a
strong induction ofmiR-208b in response to PTU. MiR-208b
is co-expressed with B-MHCandis indicative of its expres-
sion. In the miR-499 knockout animals, the induction of
miR-208b is comparable to wild-type. However, knockdown
of miR-208 in miR-499 knockout animals suppresses the
induction ofmiR-208b expression by PTU.B. Realtime PCR
analysis for miR-208, a-MHC,and B-MHCin cardiac tissue
of wild-type animals, miR-208 knockout animals, miR-499
knockout animals, and miR-499 knockout animals treated
with anti-miR-208 in the presence and absence of PTU.
DETAILED DESCRIPTION OF THE INVENTION
Cardiac and skeletal muscles respondto a variety ofpatho-
physiological stimuli such as workload, thyroid hormonesig-
naling and injury by modulating the expression of myosin
isoforms, which regulate the efficiency of contraction.
The ratio of a- to B-MHCisoformsin the adult heart is a
major determinant ofcardiac contractility. }-MHC,the major
myosin isoform in the adult heart, displays relatively low
ATPase activity, whereas a-MHChas high ATPaseactivity.
In responseto a variety of pathological stimuli such as myo-
cardial infarction, hypertension, and other disorders, 8-MHC
expression increases, while a-MHC expression decreases
with a consequent reduction in myofibrillar ATPase activity
and reduced shortening velocity ofcardiac myofibers, leading
to eventual contractile dysfunction. Remarkably, minor
changes in a-MHCcontentof the heart can have a profound
influence on cardiac performance.
Recently, the inventors reported a cardiac-specific miRNA,
miR-208a, which is encoded by an intron of the a-myosin
heavy chain gene,and is required for up-regulation ofB-MHC
expression in responseto cardiac stress and for repression of
fast skeletal muscle genesin the heart (see co-pending appli-
cation WO 2008/016924, which is herein incorporated by
reference in its entirety).
The inventors have also recently discovered that miR-208a
is also required for cardiac expression of a closely related
miRNA, miR-499, which is encoded by an intron of the
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Myh7b gene (see co-pending application PCT/US08/71837,
which is herein incorporated by reference in its entirety).
Expression of Myh7b and miR-499in the heart, as well as in
slow skeletal muscle, is controlled by the MEF2transcription
factor, a signal-dependent regulator of striated muscle gene
expression. Forced expression of miR-499 or miR-208 is
sufficient to mediate a fast to slow myofiber conversion in
vivo. MiR-208 and miR-499 can negatively regulate the
expression of Thrap1, a thyroid hormone receptor coregula-
tor, and membersofthe PUR family of transcription factors,
which in turn negatively regulate B-MHC expression in car-
diac and skeletal muscle. Sox6 functions as a repressor of
slow fiber type-specific genes. Knockdown of Sox6 expres-
sion in wild-type myotubesresults in a significant increase in
B-MHC expression. Analysis of the B-MHC promoter
revealed a Sox consensus sequence which suggests that Sox6
plays a critical role in the fiber type differentiation of fetal
skeletal muscle and B-MHCregulation in the heart. These
findings unveil a common regulatory mechanism in which
Myhgenesregulate the gene expression patterns of striated
muscles by encoding regulatory miRNAs that govern con-
tractility and signal responsiveness (van Rootj et al. (2009)
Developmental Cell, Vol. 17: 662-673).
The present invention is based, in part, on the discovery
that downregulation of both miR-208 and miR-499 in heart
cells produces a synergistic effect in suppressing the cardiac
stress response. Inhibition of miR-208a expression in heart
cells results in a reduction of stress-induced expression of
B-MHC. However, this effect is not observed until two
months following administration of the miR-208 inhibitor.
The inventors have surprisingly found that the inhibition of
both miR-208a and miR-499 result in suppression ofstress-
induced §-MHCexpression almost immediately after admin-
istration, thus accelerating the effect on the cardiac stress
response. Accordingly, strategies to manipulate skeletal and
cardiac muscle gene expression by modulating miR-208 and
miR-499 expression, either simultaneously or sequentially,
for the treatment and prevention of cardiac diseases are
described in light of these discoveries.
MiR-208ais located within an intron ofthe a-MHCgene.
The precise intron location is dependent on the particular
species and specific transcript. For example, in humans, miR-
208a is encoded within the 28” intron of the a-MHC gene,
while in mice, it is encoded within the 29” intron. The pre-
miRNA encoding sequences for miR-208a for human,
mouse,rat, and canine are shown below as SEQ ID NO:1,
SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4, respec-
tively. The mature miR-208a sequenceis provided in SEQ ID
NO: 5. Like a-MHC, miR-208a is expressed solely in the
heart.
Human pre-miR-208a
(SEQ ID No:
GATGCTCACGACGGGCGAGC TTTTGGCCCG GGTTATACCT
TATAAGACGA GCAAAAAGCT TGTTGGTCAG A
Mouse pre-miR-208a
(SEQ ID No:
GACTCTCACGACGGGTGAGC TTTTGGCCCG GGTTATACCT
TATAAGACGA GCAAAAAGCT TGTTGGTCAG A
Rat pre-miR-208a
(SEQ ID No:
GACTCTCACGACGGGTGAGC TTTTGGCCCG GGTTATACCT
TATAAGACGA GCAAAAAGCT TGTTGGTCAG A
Canine pre-miR-208a
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-continued (SEQ ID NO:ACGCATGAGC TTTTGGCTCG GGTTATACCT GATGCTCACG 4)
TATAAGACGA GCAAAAAGCT TGTTGGTCAG A
Mature miR-208a
(SEQ ID NO: 5)
AUAAGACGAGCAAAAAGCUUGU
Analysis of the genomic location of the miR-499 gene
showedit to be contained within the 20” intron ofthe Myh7b
gene, a homolog ofthe a-MHC gene. The pre-miRNAencod-
ing sequences for miR-499 for mouse, rat, human, canine,
opposum, chicken and X. tropicalis are provided in SEQ ID
NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO: 9, SEQ
ID NO:10, SEQ ID NO: 11 and SEQ ID NO:12,respectively.
SEQ ID NO: 13 is the stem-loop structure of the mouse
precursor sequence and SEQ ID NO: 14 is the mature miR-
499 sequence. The Myh7b gene is conserved in vertebrates
and is expressed solely in the heart and slow skeletal muscle
(e.g. soleus).
Mouse pre-miR-499
(SEQ ID NO:
ACTTGCAGTGTCCCTGTGTC TTGGGTGGGC AGCTGTTAAG
ATGTTTAGCT CCTCTGCATG TGAACATCAC AGCAAG
Rat pre-miR-499
(SEQ ID NO:
TTGCAGTGATTCCCTGTCTT GGGTGGGCAG CTGTTAAGAC
GTTTAGCTCC TCTCCATGTG AACATCACAG CAAG
Human pre-miR-499
(SEQ ID NO:
ACTTGCAGTGCCCCTGTGCC TTGGGCGGGC GGCTGTTAAG
ATGTTTAACT CCTCTCCACG TGAACATCAC AGCAAG
Canine pre-miR-499
(SEQ ID NO:
ACTTGCAGTGCCCTTGCACC CTGGGCGGGC GGCCGTTAAG
ATGTTTAACT CCTCTCCACG TGAACATCAC AGCAAG
Opposum pre-miR-499
(SEQ ID No:
ACTTGCAGTG
10)
CCCCTGCCTC CCCGGCGGGC AGCTGTTAAG
ATGTTTAATT CTTCTCTATG TGAACATCAC AACAAG
Chicken pre-miR-499
(SEQ ID No:
TAGATAATGT
11)
GGAGCGGCAG TTAAGACTTG TAGTGATGTT
ATTACATGGA CATCACTTTA AG
X. tropicalis pre-miR-499
(SEQ ID No:
ATGTTTAGTT
12)
GTCTTAGCGA GGCAGTTAAG ACTTGCAGTG
AAAATCTTITT CATGAACATC ACTTTAAG
Mouse stem-loop of the pre-miR-499 sequence
(SEQ ID No:
GGGUGGGCAG CUGUUAAGAC UUGCAGUGAU GUUUAGCUCC
13)
UCUGCAUGUG AACAUCACAG CAAGUCUGUG CUGCUGCCU
Mature miR-499
(SEQ ID NO: 14)
UUAAGACUUG CAGUGAUGUU U
The inventors have also discovered that the genome con-
tains a secondversion ofmiR208a, called miR-208b, which is
located within the B-MHCgeneatintron 31, and like B-MHC,
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miRNA208bis expressed solely in the heart and slow skeletal
muscle (e.g. soleus). Genes regulated by miR-208b include,
for example, Sp3, Myostatin, PURbeta, THRAP1, and fast
skeletal muscle protein genes. The sequenceofthis miRNAis
largely overlapping with miR-208a with a 100% homologyin
the “seed region,” the region that defines mRNAtargets of a
certain miRNA. Thus, miR-208b can have profound effects
on cardiac and skeletal muscle contractility in humans. The
pre-miR-208b sequenceis conserved across several mamma-
lian species (e.g. human, mouse, rat, and canine). The pre-
miR-208b sequence as well as the mature miR-208b
sequence is shown below:
pre-miR-208b
(SEQ ID NO: 18)
TTITCTGATCC GAATATAAGA CGAACAAAAG GTTTGTCTGA GGG
Mature miR-208b
(SEQ ID NO: 19)
AUAAGACGAA CAAAAGGUUU GU
It is understood that when the RNA sequences disclosed
herein are used in embodimentsthat require deoxyribonucle-
otides, athymidineresidue is substituted for a uridine residue.
Sunilarly, in embodiments requiring ribonucleotides, a uri-
dine residue is substituted for a thymidine residue in the DNA
sequences disclosed herein.
In one embodiment, the present invention provides a
method oftreating pathologic cardiac hypertrophy, myocar-
dial infarction, or heart failure in a subject in need thereof,
including a human,bytargeting the expression and/oractivity
of either or both miR-208 (e.g., miR-208a and/or miR-208b,
or in other words, miR208a/miR208b) and miR-499 in the
heart cells of the subject. In some embodiments, an inhibitor
of miR-208a/miR-208b and an inhibitor of miR-499 are
administered to the subject to reduce the expressionoractiv-
ity ofmiR-208a/miR-208b and miR-499in the heart cells of
the subject.
In another embodiment, the subject in need thereofmay be
at risk for developing pathologic cardiac hypertrophy, heart
failure, or myocardial infarction. Such a subject may exhibit
one or more risk factors including, but not limited to, long
standing uncontrolled hypertension, uncorrected valvular
disease, chronic angina, recent myocardial infarction, con-
genital predispositionto heart disease or pathological hyper-
trophy. The subject at risk may be diagnosed as having a
genetic predisposition to cardiac hypertrophy or may have a
familial history of cardiac hypertrophy.
Preferably, administration of both an inhibitor of miR-
208a/miR-208b and an inhibitor of miR-499 to the subject
results in the improvement of one or more symptoms of
cardiac hypertrophy,heart failure, or myocardial infarction in
the subject, or in the delay in the transition from cardiac
hypertrophy to heart failure. The one or more improved
symptoms maybe, for example, increased exercise capacity,
increased cardiac ejection volume,decreased left ventricular
end diastolic pressure, decreased pulmonary capillary wedge
pressure, increased cardiac output, increased cardiac index,
lowered pulmonary artery pressures, decreased left ventricu-
lar end systolic and diastolic dimensions, decreased cardiac
fibrosis, decreased collagen deposition in cardiac muscle,
decreased left and right ventricular wall stress, decreased wall
tension, increased quality of life, and decreased disease
related morbidity or mortality.
In one embodiment of the invention, the cardiac stress
responseis reducedin the subject following administration of
the miR-208(e.g., miR-208a and/or miR-208b) and miR-499
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inhibitors. The cardiac stress response includes, interalia,
cardiomyocyte hypertrophy, fibrosis of the heart, reduced
expression of a-MHCin the heart cells, and/or increased
expression of B-MHCin the heart cells. Administration of
both an inhibitor of miR-208a/miR-208b and an inhibitor of
miR-499 to the subject results in a more rapid effect on the
cardiac stress response as compared to administration of
either inhibitor alone. For instance, the reduction of the car-
diac stress response occursless than eight weeks, less than six
weeks, less than four weeks, less than three weeks, less than
two weeks, less than one week,less than five days, less than
three days, or less than one day following administration of
the inhibitors. In another embodiment, the reduction in the
cardiac stress response occurs less than twelve hours follow-
ing administration of the inhibitors.
In some embodiments, miR-208 (e.g., miR-208a and/or
miR-208b) and miR-499 inhibitors may be antisense oligo-
nucleotides targeting the mature miR-499 and/or miR-208a
or miR-208b sequences. The antisense oligonucleotides may
be ribonucleotides or deoxyribonucleotides. Preferably, the
antisense oligonucleotides have at least one chemical modi-
fication. For instance, suitable antisense oligonucleotides
may be comprised of one or more “conformationally con-
strained” or bicyclic sugar nucleoside modifications, for
example, “locked nucleic acids.” “Locked nucleic acids”
(LNAs) are modified ribonucleotides that contain an extra
bridge between the 2' and 4' carbons of the ribose sugar
moiety resulting in a “locked” conformation that confers
enhanced thermalstability to oligonucleotides containing the
LNAs. The antisense oligonucleotides targeting miR-208a/
miR-208b and miR-499 can contain combinations of LNAs
or other modified nucleotides and ribonucleotides or deox-
yribonucleotides. Alternatively, the antisense oligonucle-
otides may comprise peptide nucleic acids (PNAs), which
contain a peptide-based backbonerather than a sugar-phos-
phate backbone. Other chemical modifications that the anti-
sense oligonucleotides may contain include, but are not lim-
ited to, sugar modifications, such as 2'-O-alkyl (e.g. 2'-O-
methyl, 2'-O-methoxyethyl), 2'-fluoro, and 4' thio
modifications, and backbone modifications, such as one or
more phosphorothioate, morpholino, or phosphonocarboxy-
late linkages (see, for example, U.S. Pat. Nos. 6,693,187 and
7,067,641, which are herein incorporatedby reference in their
entireties). For instance, antisense oligonucleotides, particu-
larly those of shorter lengths (e.g., less than 15 nucleotides)
can comprise one or more affinity enhancing modifications,
such as, but not limited to, LNAs, bicyclic nucleosides,
phosphonoformates, 2'O alkyl andthe like. In some embodi-
ments, suitable antisense oligonucleotides are 2'-O-methoxy-
ethyl “gapmers” which contain 2'-O-methoxyethyl-modified
ribonucleotides on both 5' and 3' ends with at least ten deox-
yribonucleotides in the center. These “gapmers” are capable
oftriggering RNase H-dependent degradation mechanismsof
RNAtargets. Other modifications of antisense oligonucle-
otides to enhancestability and improveefficacy, such as those
described in U.S. Pat. No. 6,838,283, which is herein incor-
porated by referencein its entirety, are known in the art and
are suitable for use in the methodsofthe invention. Preferable
antisense oligonucleotides useful for inhibiting the activity of
miRNAsare about 5 to about 50 nucleotides in length, about
10 to about 30 nucleotides in length, or about 20 to about 25
nucleotides in length. In certain embodiments, antisenseoli-
gonucleotides targeting miR-208a/miR-208b and miR-499
are about 8 to about 18 nucleotides in length, and in other
embodiments about 12 to 16 nucleotidesin length. In particu-
lar, any 8-meror longer that is complementary to miR208a or
miR208b may be used, i.e., any antimir sequence that is
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complementary to any consecutive sequence in miR208a or
miR208b,starting from the 5' end of the miRto the 3' end of
the mature sequence. Antisense oligonucleotides may in
some cases comprise a sequence that is at least partially
complementary to a mature miRNA sequence,e.g. at least
about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%
complementary to a mature miRNA sequence. In some
embodiments,the antisense oligonucleotide may be substan-
tially complementary to a mature miRNA sequence,thatis at
least about 95%, 96%, 97%, 98%, or 99% complementary to
a target polynucleotide sequence. In one embodiment, the
antisense oligonucleotide comprises a sequencethat is 100%
complementary to a mature miRNA sequence.
In other embodiments, the antisense oligonucleotides are
antagomirs. “Antagomirs” are single-stranded, chemically-
modified ribonucleotides that are at least partially comple-
mentary to the miRNA sequence. Antagomirs may comprise
one or more modified nucleotides, such as 2'-O-methyl-sugar
modifications. In some embodiments, antagomirs comprise
only modified nucleotides. Antagomirs may also comprise
one or more phosphorothioate linkages resulting in a partial
or full phosphorothioate backbone.To facilitate in vivo deliv-
ery and stability, the antagomir maybe linkedto a steroid such
as cholesterol, a fatty acid, a vitamin, a carbohydrate, a pep-
tide or another small molecule ligandatits 3' end. Antagomirs
suitable for inhibiting miRNAs may be about 15 to about 50
nucleotides in length, more preferably about 18 to about 30
nucleotides in length, and most preferably about 20 to about
25 nucleotides in length.“Partially complementary”refers to
a sequencethatis at least about 75%, 80%, 85%, 90%, 95%,
96%, 97%, 98%, or 99% complementary to a target poly-
nucleotide sequence. The antagomirs maybeat least about
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%
complementary to a mature miRNA sequence. In some
embodiments, the antagomir may be substantially comple-
mentary to a mature miRNA sequence, that is at least about
95%, 96%, 97%, 98%, or 99% complementary to a target
polynucleotide sequence. In other embodiments, the antago-
mirs are 100% complementary to the mature miRNA
sequence.
In some embodiments, inhibitors of miR-499 and miR-
208a/miR-208b are antagomirs comprising a sequencethatis
perfectly complementary to the mature miR-499 and mature
miR-208a or miR-208b sequence. In one embodiment, an
inhibitor ofmiR-499 is an antagomir having a sequencethat
is partially or perfectly complementary to 5'-UUAAGACU-
UGCAGUGAUGUUU-3' (SEQ ID NO: 14). In another
embodiment, an inhibitor of miR-208a is an antagomir hav-
ing a sequencethatis partially or perfectly complementary to
5'-AUAAGACGAGCAAAAAGCUUGU-3' (SEQ ID NO:
5). In another embodiment, an inhibitor of miR-208a is an
antagomir having the sequence 5'-ACAAGCU-
UUUUGCUCGUCUUAU-3' (SEQ ID NO: 15). In still
another embodiment, an inhibitor ofmiR-208a is an antago-
mir having the sequence of SEQ ID NO: 16. In another
embodiment, an inhibitor of miR-208b is an antagomir hav-
ing a sequencethatis partially or perfectly complementary to
5'-AUAAGACGAACAAAAGGUUUGU-3' (SEQ ID NO:
19).
In some embodiments, inhibitors of miR-499 and miR-
208a or miR-208b are chemically-modified antisense oligo-
nucleotides. In one embodiment, an inhibitor ofmiR-499is a
chemically-modified antisense oligonucleotide comprising a
sequence substantially complementary to 5'-UUAAGACU-
UGCAGUGAUGUUU-3' (SEQ ID NO: 14). In another
embodiment, an inhibitor ofmiR-208a is a chemically-modi-
fied antisense oligonucleotide comprising a sequence sub-
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stantially complementary to 5'-AUAAGACGAG-
CAAAAAGCUUGU-3' (SEQ ID NO: 5). In yet another
embodiment, an inhibitor ofmiR-208b is a chemically-modi-
fied antisense oligonucleotide comprising a sequence sub-
stantially complementary to 5'-AUAAGACGAACAAAAG-
GUUUGU-3' (SEQ ID NO: 19). As used herein
“substantially complementary”refers to a sequencethatis at
least about 95%, 96%, 97%, 98%, 99%, or 100% comple-
mentary to a target polynucleotide sequence (e.g. mature or
precursor miRNA sequence).
Antisense oligonucleotides may comprise a sequence that
is substantially complementary to a precursor miRNA
sequence (pre-miRNA)for miR-499 or miR-208a/miR-208b.
In some embodiments, the antisense oligonucleotide com-
prises a sequencethat is substantially complementary to a
sequence located outside the stem-loop region of the pre-
miR-499 or pre-miR-208a/miR-208b sequence. In one
embodiment, an inhibitor ofmiR-499 function is an antisense
oligonucleotide having a sequence that is substantially
complementary to a pre-miR-499 sequence selected from the
group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID
NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11 and
SEQ ID NO: 12. In another embodiment, an inhibitor of
miR-208a function is an antisense oligonucleotide having a
sequencethat is substantially complementary to a pre-miR-
208a sequenceselected from the group consisting of SEQ ID
NO: 1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4. In
still another embodiment, an inhibitor ofmiR-208b function
is an antisense oligonucleotide having a sequence that is
substantially complementary to a pre-miR-208b sequence of
SEQ ID NO:18.
In another embodimentof the invention, a single nucleic
acid molecule may be used to inhibit both miR-208 and
miR-499 simultaneously. For instance, a single nucleic acid
may contain a sequencethat is at least partially complemen-
tary to a mature miR-208a sequence (e.g. SEQ ID NO:5) and
a sequencethatis at least partially complementary to amature
miR-499 sequence (e.g. SEQ ID NO:14). In another embodi-
ment, a single nucleic acid may contain a sequencethatis at
least partially complementary to a mature miR-208b
sequence(e.g. SEQ ID NO: 19) and a sequencethatis at least
partially complementary to a mature miR-499 sequence(e.g.
SEQ ID NO: 14). In yet another embodiment, the single
nucleic acid molecule may contain a sequencethatis at least
partially complementary to a pre-miR-208a sequence(e.g.
SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, and SEQ ID
NO:4) and a sequencethatis at least partially complementary
to a pre-miR-499 sequence(e.g. SEQ ID NO: 6, SEQ ID NO:
7, SEQ ID NO:8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID
NO: 11 and SEQ ID NO: 12). In another embodiment, the
single nucleic acid molecule may contain a sequencethatis at
least partially complementary to a pre-miR-208b sequence
(e.g. SEQ ID NO: 18) and a sequencethatis at least partially
complementary to a pre-miR-499 sequence(e.g. SEQ ID NO:
6, SEQ ID NO: 7, SEQID NO:8, SEQID NO: 9, SEQID NO:
10, SEQ ID NO: 11 and SEQ ID NO:12). The single nucleic
acid molecule may further comprise one or more spacer
nucleotides between the miR-208 (e.g., miR-208a or miR-
208b) and miR-499 targeting sequences. For instance, the
single nucleic acid molecule may contain about 1 to about 200
spacer nucleotides, more preferably about 5 to about 100
spacer nucleotides, most preferably about 10 to about 50
spacer nucleotides between the miR-208a/miR-208b and
miR-499 targeting sequences.
Anyofthe inhibitors ofmiR-208a/miR-208b and miR-499
described herein can be delivered to the target cell (e.g. heart
cell, skeletal muscle cell) by delivering to the cell an expres-
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sion vector encoding the miR-208a/miR-208b and miR-499
inhibitors. The inhibitor of miR-208a/miR-208b and the
inhibitor ofmiR-499 can be encoded by the same expression
vector. Alternatively, the inhibitor of miR-208 (e.g., miR-
208a or miR-208b) andthe inhibitor ofmiR-499 are encoded
on separate expression vectors.A “vector”is a composition of
matter which can be usedto deliver a nucleic acid of interest
to the interior ofa cell. Numerous vectors are knownin the art
including, but not limited to, linear polynucleotides, poly-
nucleotides associated with ionic or amphiphilic compounds,
plasmids, and viruses. Thus, the term “vector” includes an
autonomously replicating plasmid or a virus. Examples of
viral vectors include, but are not limited to, adenoviral vec-
tors, adeno-associated virus vectors, retroviral vectors, and
the like. An expression construct can bereplicated in a living
cell, or it can be made synthetically. For purposes of this
application, the terms “expression construct,” “expression
vector,” and “vector,” are used interchangeably to demon-
strate the application ofthe invention in a general, illustrative
sense, and are not intended to limit the invention.
In one embodiment, an expression vector for expressing an
inhibitor ofmiR-208a/miR-208b and/or miR-499 comprises
a promoter operably linked to a polynucleotide encoding an
antisense oligonucleotide, wherein the sequence of the
expressed antisense oligonucleotide is partially or perfectly
complementary to a mature sequence ofmiR-208 (e.g., miR-
208a or miR-208b) and/or miR-499. The phrase “operably
linked” or “under transcriptional control” as used herein
meansthat the promoteris in the correct location and orien-
tation in relation to a polynucleotide to control the initiation
of transcription by RNA polymerase and expression of the
polynucleotide. In another embodiment, the expression vec-
tor may encode a single nucleic acid that targets both miR-
208 (e.g., miR-208a or miR-208b) and miR-499 as described
herein, wherein the single nucleic acid is operably linked to a
promoter. In another embodiment, a single expression vector
may encode a miR-208a/miR-208b inhibitor and a miR-499
inhibitor, wherein the miR-208a/miR-208b inhibitoris driven
by a different promoter than the miR-499 inhibitor.
As used herein, a “promoter” refers to a DNA sequence
recognized by the synthetic machinery of the cell, or intro-
duced synthetic machinery, required to initiate the specific
transcription of a gene. Suitable promoters include, but are
not limited to RNApolI, poi II, pol II, and viral promoters
(e.g. human cytomegalovirus (CMV) immediate early gene
promoter, the SV40 early promoter, and the Rous sarcoma
virus long terminalrepeat). In one embodiment, the promoter
is a tissue specific promoter. Ofparticular interest are muscle
specific promoters, and more particularly, cardiac specific
promoters. These include the myosin light chain-2 promoter
(Franzet al. (1994) Cardioscience, Vol. 5(4):235-43; Kelly et
al. (1995) J. Cell Biol., Vol. 129(2):383-396), the alpha actin
promoter (Moss et al. (1996) Biol. Chem., Vol. 271(49):
31688-31694), the troponin 1 promoter (Bhavsar etal. (1996)
Genomics, Vol. 35(1):11-23); the Na+/Ca2+ exchangerpro-
moter (Barnes et al. (1997) J Biol. Chem., Vol. 272(17):
11510-11517), the dystrophin promoter (Kimuraet al. (1997)
Dev. Growth Differ., Vol. 39(3):257-265), the alpha7 integrin
promoter (Ziober and Kramer (1996) J Bio. Chem., Vol.
271(37):22915-22), the brain natriuretic peptide promoter
(LaPointe et al. (1996) Hypertension, Vol. 27Pt 2):715-22)
and the alpha B-crystallin/small heat shock protein promoter
(Gopal-Srivastava (1995) J. Mol. Cell. Biol., Vol. 15(12):
7081-7090), alpha myosin heavy chain promoter (Yamauchi-
Takihara et al. (1989) Proc. Natl. Acad. Sci. USA, Vol. 86(10):
3504-3508) and the ANF promoter (LaPointeet al. (1988) /.
Biol. Chem., Vol. 263(19):9075-9078).
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In certain embodiments, the promoter operably linked to a
polynucleotide encoding a miR-499 and/or a miR-208a/miR-
208b inhibitor may be an inducible promoter. Inducible pro-
moters are knownin the art and include,butare notlimited to,
tetracycline promoter, metallothionein IIA promoter, heat
shock promoter, steroid/thyroid hormone/retinoic acid
response elements, the adenovirus late promoter, and the
inducible mouse mammary tumorvirus LTR. An expression
vector may encode a single nucleic acid that targets both
miR-208 (e.g., miR-208a or miR-208b) and miR-499 as
described herein, wherein the single nucleic acid is operably
linked to a inducible promoter. Alternatively, a single expres-
sion vector may encode a miR-208a/miR-208b inhibitor and
amiR-499 inhibitor, wherein the miR-208a/miR-208b inhibi-
tor is driven bya first inducible promoter and the miR-499
inhibitor is driven by a second inducible promoter. In another
embodiment, a first expression vector may encode a miR-
208a/miR-208b inhibitor, wherein the miR-208a/miR-208b
inhibitor is operably linkedto afirst inducible promoter and a
second expression vector may encode a miR-499 inhibitor,
wherein the miR-499 inhibitoris operably linked to a second
inducible promoter. Other combinations of inducible and
constitutive promoters for controlling the expression of the
miR-208 (e.g., miR-208a or miR-208b) and miR-499 inhibi-
tors are also contemplated. For instance, a miR-208a/miR-
208b inhibitor may be expressed from a vector using a con-
stitutive promoter, while a miR-499 inhibitor may be
expressed from a vector using an inducible promoter.
The present invention also includes methods for scaveng-
ing or clearing miR-499 and miR-208a/miR-208b inhibitors
following treatment. The method may comprise overexpress-
ing binding sites for the miR-499 and miR-208a/miR-208b
inhibitors in cardiac tissue. In another embodiment, the
present invention provides a method for scavengingor clear-
ing miR-499 and miR-208 (e.g., miR-208a or miR-208b)
following treatment. In one embodiment, the method com-
prises overexpression ofbindingsite regions for miR-499 and
miR-208a/miR-208b in skeletal muscle using a skeletal and
heart muscle specific promoter (muscle creatine kinase
(MCK)). The binding site regions preferably contain a
sequence of the seed region for miR-499 and miR-208a or
miR-208b. The seed region is the 5' portion of a miRNA
spanning bases 2-8, which is important for target recognition.
In some embodiments, the binding site may contain a
sequencefrom the 3'UTRofone or moretargets ofmiR-499
or miR-208, such as THRAP1 or PURbeta. In another
embodiment, a miR-499 and miR-208 inhibitor may be
administered after miR-499 and miR-208to attenuate or stop
the function of the miRNA.
In another embodiment of the invention, the inhibitor of
miR-208 (e.g., miR-208a or miR-208b) and the inhibitor of
miR-499 are co-administered. The miR-208 inhibitor and
miR-208 may be administered in a single formulation. For
instance, a pharmaceutical composition comprising a miR-
208 inhibitor and a miR-499 inhibitor can be used to co-
administer the two inhibitors. Alternatively, the miR-208 and
miR-499 inhibitors may be encoded bya single nucleic acid,
such as an expression vector as described herein. Multiple
co-administrations of the two inhibitors can be given over a
sustained period of time, for instance, one week, two weeks,
three weeks, one month, two months, three months, four
months, five months, six months, nine months, one year, two
years, three years, four years, or five years.
In some embodiments, the inhibitor ofmiR-208(e.g., miR-
208a or miR-208b) and the inhibitor of miR-499 are admin-
istered sequentially. In one embodiment, the inhibitor ofmiR-
208 is administered prior to the inhibitor of miR-499. In
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another embodiment, the inhibitor of miR-499 is adminis-
tered prior to the inhibitor ofmiR-208. The interval separat-
ing the administration ofthe miR-208 and miR-499 inhibitors
may range from several minutes to several days. For instance,
the interval can be about one hourto about 72 hours, six hours
to about 48 hours, or about 12 hours to about 24 hours. In a
preferred embodiment, the interval between the administra-
tion of the miR-208 inhibitor and the miR-499 inhibitor is at
least 24 hours. The inventors have observed that administer-
ing a miR-499 inhibitor at least about 24 hours before a
miR-208 inhibitor results in at least about a 50% reduction in
stress-induced B-MHC expression at about three days after
administration of the miR-208 inhibitor. In the absence of a
miR-499 inhibitor, a comparable effect on stress-induced
B-MHCexpression is not observed until at least about two
months after administration of the miR-208 inhibitor.
In other embodiments of the invention, more than one
sequential administration of the miR-208 and miR-499
inhibitors may be employed to producea sustained effect. In
this regard, various combinations may be used. By way of
illustration, where the inhibitor of miR-499 is “A” and the
inhibitor of miR-208 (e.g., miR-208a or miR-208b) is “B”,
the following permutations based on 3 and 4 total adminis-
trations are exemplary:
 
A/B/A B/A/B B/B/A A/A/B B/A/A A/B/B
B/B/B/A B/B/A/B- A/A/B/B-A/B/A/B-A/B/B/A_B/B/A/A
B/A/B/A_ B/A/A/B-B/B/B/A- A/AJA/B- OB/A/A/A A/B/AJA
A/A/B/A_ A/B/B/B__B/A/B/B___ B/B/A/B
Other combinationsare likewise contemplated.
Preferably, the expression or activity of miR-208 (e.g.,
miR-208a or miR-208b) and miR-499 is reduced in the heart
cells of a subject following administration of the miR-208
inhibitor and the miR-499 inhibitor to the subject. In certain
embodiments, the expression or activity of miR-208a/miR-
208b and/or miR-499is reduced by greater than 50%, greater
than 60%, greater than 70%, greater than 75%, greater than
80%, greater than 85%,greater than 90%,or greater than 95%
following administration of a miR-208 and miR-499 inhibi-
tor. In one embodiment, the expression or activity of miR-
208a/miR-208b and miR-499 is reduced by greater than 60
percentin the heart cells ofthe subject following administra-
tion of the inhibitors. In another embodiment, the expression
or activity of miR-208a/miR-208b and miR-499 is reduced
by greater than 80 percent in the heart cells of the subject
following administration of the inhibitors. In still another
embodiment, the expression or activity of miR-208a/miR-
208b and miR-499is reducedby greater than 90 percent in the
heart cells of the subject following administration of the
inhibitors.
Thepresent invention also includes a methodofregulating
cardiac and/or skeletal muscle contractility. Adult skeletal
muscle fibers can be categorized into fast and slow twitch
subtypes based on specialized contractile and metabolic
properties. These properties reflect the expression of specific
sets of fast and slow contractile protein isoforms of myosin
heavy andlight chains, tropomyosin, and troponins, as well as
myoglobin (Naya et al. (2000) J Biol Chem, Vol. 275(7):
4545-4548). Slow-twitch muscles are primarily used in
chronic activities such as posture maintenance and sustained
locomotoractivity. Fast-twitch fibers are used primarily for
high-force burst activities. The adult skeletal muscle pheno-
type is not static but instead retains the ability to adjust to
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variations in load bearing and contractile usage patterns,
resulting in adaptations in morphology, phenotype, and con-
tractile properties.
The up-regulation of several fast skeletal muscle contrac-
tile protein genes wasobservedin the hearts of mice lacking
both miR-208a alleles. This up-regulation of fast skeletal
muscle contractile protein genes in the hearts of miR-208a
knockout mice indicates that miR-208 normally functions to
repress the fast skeletal muscle gene program. A concomitant
reduction ofmiR-499 expression was observed in miR-208a
mutant mice (see Example 3), suggesting that miR-499 may
also negatively regulate the expressionoffast skeletal muscle
contractile protein genes. As discussed above, miR-208b is
also expressed predominantly in slow skeletal muscle (e.g.,
soleus). Thus, miR-208b may have profoundeffects on car-
diac and skeletal muscle contractility in humans, and may
also regulate the fast skeletal muscle gene program anddeter-
mine fiber identity. The inventors have recently shown that
miR-208b and miR-499 play important roles in the specifi-
cation ofmuscle fiber identity by activating slow and repress-
ing fast myofiber gene programs. Theactions of these miR-
NAsare mediated in part by a collection of transcriptional
repressors of slow myofiber genes,like Sox6, PURB, Sp3 and
HP1. Using the skeletal muscle specific MCK-promoter
miR-499 transgenic animals also revealed conversion to a
slower myofiber type. Even more remarkably, when mice
were subjected to a regimen of forced treadmill running, the
miR-499 transgenic animals ran more than 50% longer than
wild-type littermates, indicative of enhanced endurance
resulting from the reprogramming of fast myofibers to a
slowerfiber type. See van Rooij et al. (2009) Developmental
Cell, Vol. 17:662-673).
In one embodiment, the methodofregulating cardiac and/
or skeletal muscle contractility comprises administering a
modulator ofmiR-499 and miR-208 (e.g., miR-208a or miR-
208b) expression or activity to heart and/or skeletal muscle
cells. In another embodiment, the method comprises admin-
istering a modulator of miR-499 and miR-208b. In another
embodiment, there is provided a method ofregulating cardiac
contractile protein gene expression comprising administering
a modulator of miR-499 and miR-208 (e.g., miR-208a or
miR-208b) expression or activity to heart cells. In another
embodiment, there is provided a method of regulating skel-
etal muscle contractile protein gene expression comprising
administering to skeletal muscle cells a modulator of miR-
499 and miR-208 (e.g., miR-208a or miR-208b) expression
or activity. In another embodiment, there is provided a
methodofregulating skeletal muscle contractile protein gene
expression comprising administering to skeletal muscle cells
a modulator ofmiR-499 andmiR-208b expressionoractivity.
In still another embodiment, the present invention provides a
methodof inducing a fiber type switch of a skeletal muscle
cell comprising administering to skeletal muscle cells a
modulator ofmiR-499 and miR-208 expressionoractivity to
the skeletal muscle cell. In another embodiment, the method
of inducing a fiber type switch of a skeletal muscle cell
comprises administering to skeletal muscle cells a modulator
ofmiR-499 and miR-208b expression or activity. The modu-
lator may be an agonistor an inhibitor ofmiR-499, miR-208,
and/or miR-208b expression or activity. In some embodi-
ments, the expression ofTHRAP1, PURbeta, myostatin, Sp3,
HP 18, and Sox 6 are increasedin a cell by contacting the cell
with a miR-499 and miR-208a (or miR-208b) inhibitor. In
other embodiments, expression ofTHRAP1, PURbeta, myo-
statin, Sp3, HP 16, and Sox 6 are decreased in a cell by
contacting the cell with an agonist ofmiR-499 and miR-208a
(or miR-208b).
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In certain embodimentsofthe invention, there is provided
a method of reducing B-MHCexpression in heart cells com-
prising administering an inhibitor of miR-499 and miR-208
(e.g., miR-208a or miR-208b) expression or activity to the
heart cells. In one embodiment, there is provided a method of
reducing B-MHCexpression in skeletal muscle cells com-
prising administering an inhibitor ofmiR-499 and miR-208b
expression or activity to the skeletal muscle cells. In other
embodiments of the invention, there is provided a method of
elevating B-MHC expression in heart cells and/or skeletal
muscle cells comprising increasing endogenous miR-499 and
miR-208a (or miR-208b) expression or activity or adminis-
tering exogenous miR-499 and miR-208a (or miR-208b) to
heart cells and/or skeletal muscle cells.
In one embodiment of the invention, there is provided a
method ofincreasing the expression ofa fast skeletal muscle
contractile protein gene in heart cells comprising administer-
ing to the heart cells an inhibitor of miR-499 and miR-208
(e.g., miR-208a or miR-208b) expression or activity. In
another embodiment, there is provided a methodof increas-
ing the expression of afast skeletal muscle contractile protein
gene in skeletal muscle cells comprising administering to the
skeletal muscle cells an inhibitor ofmiR-499 and miR-208b
expression or activity. In another embodimentof the inven-
tion, there is provided a method of decreasing the expression
ofa fast skeletal muscle contractile protein gene in heart cells
and/or skeletal muscle cells comprising increasing endog-
enous miR-499 and miR-208a (or miR-208b) expression or
activity or administering exogenous miR-499 and miR-208a
(or miR-208b) to the heart cells and/or skeletal muscle cells.
Examples of fast skeletal muscle contractile protein genes
that may be increased or decreased according to the methods
ofthe present invention include, but are not limited to, tropo-
nin 12; troponin T3, fast skeletal myosin light chain,or alpha
skeletal actin.
In skeletal muscle, the repression of slow fiber genes and
activation of fast fiber genes is associated with numerous
musculoskeletal disorders, including, but not limitedto, dis-
use atrophy, muscle wasting in response to anti-gravity, and
denervation. Thus, expression of miR-499 in combination
with miR-208a or miR-208b in skeletal muscle cells may be
useful in repressing fast fiber genes thereby activating the
reciprocal expression of slow fiber genes. Accordingly, the
present invention also encompasses a methodfortreating or
preventing a musculoskeletal disorder in a subject in need
thereof. In one embodiment, the method comprises adminis-
tering an agonist of miR-208 (e.g., miR-208a or miR-208b)
and an agonist ofmiR-499 to the subject, wherein the expres-
sion or activity of miR-208a/miR-208b and miR-499 is
increased in the skeletal muscle cells ofthe subject following
administration. In another embodiment, the method com-
prises administering an agonist of miR-208b and an agonist
ofmiR-499 to the subject, wherein the expression or activity
ofmiR-208b and miR-499is increased in the skeletal muscle
cells of the subject following administration. Preferably, the
expression of one or more fast skeletal muscle genes in the
skeletal muscle cells of the subject is reduced following
administration of the miR-499 and miR-208a (or miR-208b)
agonists. The one or more fast skeletal muscle genes can
include, but is not limited to, troponin 12, troponin T3, fast
skeletal myosin light chain, and alpha skeletal actin.
In another embodiment, the present invention provides a
methodoftreating or preventing muscle wasting in response
to areduced gravity environment by administering an agonist
ofmiR-499 andmiR-208(e.g., miR-208a or miR-208b)to the
skeletal muscle. In another embodiment, the methodoftreat-
ing or preventing muscle wasting in response to a reduced
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gravity environment comprises administering an agonist of
miR-499 and miR-208bto the skeletal muscle. In yet another
embodiment, the present invention provides a method of
treating or preventing muscle atrophy by administering an
agonist of miR-499 and an agonist of miR-208 (e.g., miR-
208a and/or miR-208b) to the skeletal muscle. In another
embodiment, the method of treating or preventing muscle
atrophy comprises administering an agonist of miR-499 and
an agonist of miR-208b to the skeletal muscle.
In some embodiments, the agonist of miR-208 (miR208a
ormiR-208b) and the agonist ofmiR-499 are polynucleotides
encoding a mature miR-208 (miR208a or miR-208b) and/or
miR-499 sequence. In one embodiment, the polynucleotide
comprises a mature miR-208a sequence (SEQ ID NO:5) and
a mature miR-499 sequence (SEQ ID NO:14). In another
embodiment, the polynucleotide comprises a mature miR-
208b sequence (SEQ ID NO: 19) and a mature miR-499
sequence (SEQ ID NO: 14). In another embodiment, the
agonist of miR-499 and agonist of miR-208 (miR208a or
miR-208b) may be a polynucleotide comprising the pri-
miRNA or pre-miRNA sequence for miR-499 and miR-208
(miR208a or miR-208b). Alternatively, the agonist of miR-
208 (miR208a or miR-208b) and the agonist ofmiR-499 may
be separate polynucleotides each comprising a mature
sequence or pre-miRNA sequenceofthe miRNA.Thepoly-
nucleotide comprising the mature miR-499 and/or miR-208
(miR208a or miR-208b) sequence maybesingle stranded or
double stranded. The polynucleotides may contain one or
more chemical modifications, such as locked nucleic acids,
peptide nucleic acids, sugar modifications, such as 2'-O-alkyl
(e.g. 2'-O-methyl, 2'-O-methoxyethyl), 2'-fluoro, and 4' thio
modifications, and backbone modifications, such as one or
more phosphorothioate, morpholino, or phosphonocarboxy-
late linkages. In one embodiment, the polynucleotide com-
prising a miR-499, miR-208, and/or miR-208b sequenceis
conjugated to cholesterol.
In another embodiment, the agonist ofmiR-499 and miR-
208 (miR208a or miR-208b) may be encoded on an expres-
sion vector. An expression vectorfor expressing miR-499 and
miR-208 (miR208a or miR-208b) comprisesat least one pro-
moter operably linked to a polynucleotide encoding miR-499
and/or miR-208 (miR208a ormiR-208b). The polynucleotide
encoding miR-499 may encode the primary-miRNA-499
sequence (pri-miR-499), the precursor-miRNA-499
sequence (pre-miR-499) or the mature miR-499 sequence.
The polynucleotide encoding miR-208a/miR-208b may
encode the primary-miRNA-208a/208b sequence (pri-miR-
208/pri-miR-208b), the —_precursor-miRNA-208/208b
sequence (pre-miR-208a/pre-miR-208b) or the mature miR-
208a/208b sequence. In some embodiments, the expression
vector comprises a polynucleotide operably linked to a pro-
moter, wherein said polynucleotide comprises the sequence
ofSEQIDNO:5 and SEQ ID NO:14.In other embodiments,
the expression vector comprises a polynucleotide operably
linked to a promoter, wherein said polynucleotide comprises
the sequence of SEQ ID NO: 19 and SEQ ID NO:14. Such
polynucleotides may be about 18 to about 2000 nucleotides in
length, about 70 to about 200 nucleotides in length, about 20
to about 50 nucleotides in length, or about 18 to about 25
nucleotides in length. In another embodiment, the expression
vector may express a miR-499 agonist (e.g. polynucleotide
comprising a miR-499 sequence) and a miR-208 agonist(e.g.
polynucleotide comprising a miR-208a or miR-208b
sequence) from different promoters. Polynucleotides encod-
ing miR-499, miR-208a, and/or miR-208b may be located in
anucleic acid encoding an intron or ina nucleic acid encoding
an untranslated region ofan mRNAorin a non-coding RNA.
10
15
20
25
30
35
40
45
50
55
60
65
18
In one embodiment, the expression vector may contain
sequences from the 20” intron from the Myh7b gene or
sequencesfrom the 31°intron from the Myh7 (B-MHC)gene.
The agonist of miR-208a or miR-208b may be co-admin-
istered with the agonist of miR-499 to a subject. The two
agonists may be administered in a single formulation, e.g. a
pharmaceutical composition comprising a miR-208a or miR-
208b agonist and a miR-499 agonist. Alternatively, the two
agonists (e.g. miR-208a and miR-499 or miR-208b and miR-
499) may be a single polynucleotide encoding the mature or
pre-miRNA sequence of the two miRNAs. Multiple co-ad-
ministrations ofthe two agonists canbe given over a sustained
period of time, for instance, one week, two weeks, three
weeks, one month, two months, three months, four months,
five months, six months, nine months, one year, two years,
three years, four years, or five years.
In certain embodiments, the agonist of miR-208a or miR-
208b and the agonist of miR-499 are administered sequen-
tially. In one embodiment, the agonist of miR-208a or miR-
208b is administered prior to the agonist of miR-499. In
another embodiment, the agonist ofmiR-499 is administered
prior to the agonist of miR-208a or miR-208b. The interval
separating the administration ofthe agonists may range from
several minutes to weeks, e.g. about one hour to about 72
hours, six hours to about 48 hours, or about 12 hours to about
24 hours. Ina preferred embodiment, the interval between the
administration ofthe miR-208a or miR-208b agonist and the
miR-499 agonistis at least 24 hours.
The present invention also includes pharmaceutical com-
positions comprising an inhibitor or agonist of miR-499,
miR-208a, and/or miR-208b. Whereclinical applications are
contemplated, pharmaceutical compositions will be prepared
in a form appropriate for the intended application. Generally,
this will entail preparing compositions that are essentially
free of pyrogens, as well as other impurities that could be
harmful to humansor animals.
In one embodiment, the pharmaceutical composition com-
prises an effective dose of a miR-499 inhibitor and/or an
effective dose of a miR-208a or miR-208b inhibitor. In
another embodiment, the pharmaceutical composition com-
prises an effective dose of a miR-499 agonist and/oran effec-
tive dose of a miR-208a or miR-208b agonist. An “effective
dose” is an amountsufficient to effect a beneficial or desired
clinical result. An effective dose of an miRNA inhibitor or
miRNA agonist of the invention may be about 1 mg/kg to
about 200 mg/kg, about 20 mg/kg to about 160 mg/kg, or
about 40 mg/kg to about 100 mg/kg. In one embodiment, the
inhibitor of miR-208 or miR-208b andthe inhibitor of miR-
499 are administered each at a dosage of about 20 mg/kg to
about 200 mg/kg. In another embodiment, the inhibitor of
miR-208 or miR-208b and the inhibitor of miR-499 are
administered each at a dosage of about 80 mg/kg. In another
embodiment, the agonist of miR-208 or miR-208b and the
agonist ofmiR-499 are administered each at a dosage ofabout
20 mg/kg to about 200 mg/kg.In still another embodiment,
the agonist ofmiR-208 or miR-208b and the agonist ofmiR-
499 are administered each at a dosage ofabout 80 mg/kg. The
precise determination ofwhat would be considered an effec-
tive dose may be based onfactors individual to each patient,
including their size, age, type of disorder (e.g. myocardial
infarction, heart failure, cardiac hypertrophy, or musculosk-
eletal), and nature of inhibitor or agonist (e.g. antagomir,
expression construct, antisense oligonucleotide, etc). There-
fore, dosages can be readily ascertained by those of ordinary
skill in the art from this disclosure and the knowledge in the
art.
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Colloidal dispersion systems, such as macromolecule
complexes, nanocapsules, microspheres, beads, and lipid-
based systems including oil-in-water emulsions, micelles,
mixed micelles, and liposomes, may be used as delivery
vehicles for the oligonucleotide inhibitors of miRNA func-
tion, polynucleotides encoding miRNA agonists, or con-
structs expressing particular miRNA inhibitors or agonists.
Commercially available fat emulsions that are suitable for
delivering the nucleic acids of the invention to cardiac and
skeletal muscle tissues include Intralipid®, Liposyn®, Lipo-
syn® II, Liposyn® III, Nutrilipid, and other similar lipid
emulsions. A preferred colloidal system for use as a delivery
vehicle in vivo is a liposome(i.e., an artificial membrane
vesicle). The preparation and use of such systems is well
knownin the art. Exemplary formulations are also disclosed
in USS. Pat. No. 5,981,505; US. Pat. No. 6,217,900; U.S. Pat.
No. 6,383,512; U.S. Pat. No. 5,783,565; U.S. Pat. No. 7,202,
227; USS. Pat. No. 6,379,965; U.S. Pat. No. 6,127,170; U.S.
Pat. No. 5,837,533; U.S. Pat. No. 6,747,014; and WO03/
093449, which are herein incorporated by reference in their
entireties.
One will generally desire to employ appropriate salts and
buffers to render delivery vehicles stable and allow for uptake
by target cells. Aqueous compositions of the present inven-
tion comprise an effective amount of the delivery vehicle
comprising the inhibitor polynucleotides or miRNA poly-
nucleotide sequences(e.g. liposomes or other complexes or
expression vectors) dissolved or dispersed in a pharmaceuti-
cally acceptable carrier or aqueous medium. The phrases
“pharmaceutically acceptable” or “pharmacologically
acceptable”refers to molecular entities and compositions that
do not produce adverse,allergic, or other untoward reactions
when administered to an animal or a human.As used herein,
“pharmaceutically acceptable carrier” includes solvents,
buffers, solutions, dispersion media, coatings, antibacterial
and antifungal agents, isotonic and absorption delaying
agents andthe like acceptable for use in formulating pharma-
ceuticals, such as pharmaceuticals suitable for administration
to humans. The use of such media and agents for pharmaceu-
tically active substances is well known in the art. Except
insofar as any conventional media or agent is incompatible
with the active ingredients of the present invention,its use in
therapeutic compositions is contemplated. Supplementary
active ingredients also can be incorporated into the composi-
tions, provided they do not inactivate the vectors or poly-
nucleotides of the compositions.
The active compositions of the present invention may
include classic pharmaceutical preparations. Administration
ofthese compositions accordingto the present invention may
be via any common route so long as the target tissue is
available via that route. This includes oral, nasal, or buccal.
Alternatively, administration may be by intradermal, subcu-
taneous, intramuscular, intraperitoneal or intravenousinjec-
tion, or by direct injection into cardiac tissue. Pharmaceutical
compositions comprising miRNA inhibitors, polynucleotides
encoding miRNA sequence or expression constructs com-
prising miRNA sequences may also be administered by cath-
eter systems or systemsthat isolate coronary circulation for
delivering therapeutic agents to the heart. Various catheter
systems for delivering therapeutic agents to the heart and
coronary vasculature are knownin the art. Some non-limiting
examples of catheter-based delivery methods or coronary
isolation methods suitable for use in the present invention are
disclosed in U.S.Pat. No. 6,416,510; U.S. Pat. No. 6,716,196;
US. Pat. No. 6,953,466, WO 2005/082440, WO 2006/
089340, U.S. Patent Publication No. 2007/0203445, US.
Patent Publication No. 2006/0148742, and U.S. Patent Pub-
10
20
25
30
35
40
45
50
55
60
65
20
lication No. 2007/0060907, whichare all herein incorporated
by reference in their entireties. Such compositions would
normally be administered as pharmaceutically acceptable
compositions as described herein.
The active compounds mayalso be administered parenter-
ally or intraperitoneally. By wayofillustration, solutions of
the active compounds as free base or pharmacologically
acceptable salts can be prepared in water suitably mixed with
a surfactant, such as hydroxypropylcellulose. Dispersions
can also be preparedin glycerol, liquid polyethylene glycols,
and mixtures thereofandin oils. Under ordinary conditions of
storage and use, these preparations generally contain a pre-
servative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use or
catheter delivery include, for example, sterile aqueous solu-
tionsor dispersions andsterile powders for the extemporane-
ous preparation ofsterile injectable solutions or dispersions.
Generally, these preparationsare sterile and fluid to the extent
that easy injectability exists. Preparations should be stable
under the conditions of manufacture and storage and should
be preserved against the contaminating action ofmicroorgan-
isms, such as bacteria and fungi. Appropriate solvents or
dispersion media may contain, for example, water, ethanol,
polyol (for example, glycerol, propylene glycol, and liquid
polyethylene glycol, and thelike), suitable mixtures thereof,
and vegetable oils. The proper fluidity can be maintained, for
example, by the use of a coating, such as lecithin, by the
maintenance of the required particle size in the case of dis-
persion and by the use of surfactants. The prevention of the
action of microorganisms can be brought about by various
antibacterial an antifungal agents, for example, parabens,
chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
In manycases,it will be preferable to include isotonic agents,
for example, sugars or sodium chloride. Prolonged absorp-
tion of the injectable compositions can be brought about by
the use in the compositions ofagents delaying absorption, for
example, aluminum monostearate and gelatin.
Sterile injectable solutions maybe prepared by incorporat-
ing the active compounds in an appropriate amount into a
solvent along with any other ingredients (for example as
enumerated above) as desired, followedbyfiltered steriliza-
tion. Generally, dispersions are prepared by incorporating the
various sterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium andthe desired
other ingredients, e.g., as enumerated above. In the case of
sterile powders for the preparation ofsterile injectable solu-
tions, the preferred methods of preparation include vacuum-
drying and freeze-drying techniques which yield a powder of
the active ingredient(s) plus any additional desired ingredient
from a previously sterile-filtered solution thereof.
The compositions of the present invention generally may
be formulated in a neutral or salt form. Pharmaceutically-
acceptable salts include, for example, acid addition salts
(formed with the free amino groupsofthe protein) derived
from inorganic acids (e.g., hydrochloric or phosphoric acids,
or from organic acids (e.g., acetic, oxalic, tartaric, mandelic,
and thelike. Salts formed with the free carboxyl groups ofthe
protein can also be derived from inorganic bases (e.g.,
sodium, potassium, ammonium,calcium, or ferric hydrox-
ides) or from organic bases(e.g., isopropylamine, trimethy-
lamine,histidine, procaine andthe like.
Upon formulation, solutionsare preferably administered in
a manner compatible with the dosage formulation and in such
amountas is therapeutically effective. The formulations may
easily be administered in a variety of dosage forms such as
injectable solutions, drug release capsules and the like. For
parenteral administration in an aqueous solution, for
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example, the solution generally is suitably buffered and the
liquid diluentfirst rendered isotonic for example with suffi-
cient saline or glucose. Such aqueoussolutions may be used,
for example, for intravenous, intramuscular, subcutaneous
and intraperitoneal administration. Preferably, sterile aque-
ous media are employed as is knownto thoseofskill in theart,
particularly in light of the present disclosure. By way of
illustration, a single dose maybe dissolved in 1 ml ofisotonic
NaC]solution and either added to 1000 ml ofhypodermocly-
sis fluid or injected at the proposedsite of infusion, (see for
example, “Remington’s Pharmaceutical Sciences” 15th Edi-
tion, pages 1035-1038 and 1570-1580). Some variation in
dosage will necessarily occur depending on the condition of
the subject being treated. The person responsible for admin-
istration will, in any event, determine the appropriate dose for
the individual subject. Moreover, for human administration,
preparations should meetsterility, pyrogenicity, general
safety and purity standards as required by FDA Office of
Biologics standards.
Any of the compositions described herein may be com-
prised in a kit. In one embodiment, the kit contains a first
pharmaceutical composition comprising a miR-208a or miR-
208b inhibitor and a second pharmaceutical composition
comprising a miR-499 inhibitor. In another embodiment, the
kit contains a single pharmaceutical composition comprising
a miR-208a or miR-208b inhibitor and a miR-499 inhibitor.
In another embodiment, the kit containsa first pharmaceutical
composition comprising a miR-208a or miR-208b agonist
and a second pharmaceutical composition comprising a miR-
499 agonist. In still another embodiment, the kit contains a
single pharmaceutical composition comprising a miR-208a
ormiR-208b agonist and a miR-499 agonist. In some embodi-
ments, the kit may also include one or more transfection
reagent(s) to facilitate delivery of the miRNA agonists or
inhibitors to cells.
The components of the kits may be packaged either in
aqueous media or in lyophilized form. The container means
of the kits will generally include at least one vial, test tube,
flask, bottle, syringe or other container means, into which a
component maybeplaced, and preferably, suitably aliquoted.
Wherethere is more than one componentin the kit, the kit also
will generally contain a second, third or other additional
containerinto which the additional components maybe sepa-
rately placed(e.g.sterile, pharmaceutically acceptable buffer
and/or other diluents). However, various combinations of
components may be comprised in a vial. The kits of the
present invention also will typically include a means for con-
taining the nucleic acids, and any other reagent containers in
close confinement for commercial sale. Such containers may
include injection or blow molded plastic containers into
whichthe desired vials are retained.
Whenthe componentsofthe kit are provided in one and/or
moreliquid solutions, the liquid solution is an aqueous solu-
tion, with a sterile aqueous solution being particularly pre-
ferred.
However, the components of the kit may be provided as
dried powder(s). When reagents and/or componentsare pro-
vided as a dry powder, the powder can be reconstituted by the
addition ofa suitable solvent. It is envisioned that the solvent
mayalso be provided in another container means.
Such kits may also include components that preserve or
maintain the miRNA agonist or miRNA inhibitors or that
protect against their degradation. Such components may be
DNAse-free, RNAse-free or protect against nucleases (e.g.
RNAses and DNAses). Such kits generally will comprise, in
suitable means,distinct containers for each individual reagent
or solution.
10
15
20
25
30
35
40
45
50
55
60
65
22
A kit will also include instructions for employing the kit
components as well the use ofany other reagent not included
in the kit. Instructions may include variations that can be
implemented. A kit may also include utensils or devices for
administering the miRNA agonist or inhibitor by various
administration routes, such as parenteral or catheter admin-
istration.
It is contemplated that such reagents are embodiments of
kits ofthe invention. Such kits, however, are notlimited to the
particular items identified above and may include any reagent
used for the manipulation or characterization of miRNA.
The following examples are included solely to illustrate
various aspects of the invention. The reference to miR208 in
the Examplesandfigure refers to miR208a in mice. However,
those of skill in the art should, in light of the present disclo-
sure, appreciate that the invention is equally applicable to any
humanorother animal, and encompasses modulating either
miR208a and/or miR208b.
EXAMPLES
Example 1
MiR-208 Knockout Mice Exhibit Reduced Cardiac
Hypertrophy and Fibrosis in Response to Pressure
Overload
Encoded within an intron ofthe a-MHCgene is miR-208.
Like a-MHC, miR-208is expressed specifically in the heart
with trace expression in the lung. miR-208 is processed out of
the a-MHC pre-mRNArather than being transcribed as a
separate transcript. Intriguingly, however, miR-208 displays
aremarkably long half-life ofat least 14 days, and canthereby
exert functions even when a-MHC mRNA expression has
been down-regulated.
MiR-208 knockout mice were created by generating a
miR-208 targeting vector by digesting a 0.4 kb fragment(5'
arm) extending upstream of the miR-208 coding region with
SacI] and NotI and ligating the fragment into the
pGKneoF2L2dta targeting plasmid upstream ofthe loxP sites
and the Frt-flanked neomycin cassette. A 3.3 kb fragment (3'
arm) was digested with SalI and HindIII andligated into the
vector between the neomycin resistance and Dta negative
selection cassettes. Targeted ES-cells carrying the disrupted
allele were identified by Southern blot analysis with 5' and 3'
probes. Three miR-208 targeted ES clones were identified
and usedfor blastocyst injection. The resulting chimeric mice
were bred to C57BL/6to obtain germline transmission ofthe
mutantallele.
Although genetic deletion of miR-208 in mice failed to
induce an overt phenotype, microarray analysis on hearts
from wild-type and miR-208-/- animals at 2 months of age
revealed removal ofmiR-208to result in pronounced expres-
sion of numerous fast skeletal muscle contractile protein
genes, which are normally not expressed in the heart. Thus,
these results suggest that undernormal conditions miR-208is
co-expressed with the sole cardiac-specitic MHC geneto
maintain cardiomyocyte identity by repressing the expression
of skeletal muscle genesin the heart.
The most remarkable function ofmiR-208 wasrevealed by
the aberrant response ofmiR-208 null mice to cardiac stress
(van Rooij et al., (2007) Science, Vol. 316: 575-579). In
response to pressure overload by thoracic aortic banding
(TAB)that drives pathological remodeling of the heart, his-
tological sections of hearts from miR-208 knockout mice
showedvirtually no hypertrophy ofcardiomyocytes or fibro-
sis as comparedto sections from wild-type mice (FIG. 1A). In
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addition, miR-208 knockout animals were unable to up-regu-
late B-MHC expression in response to pressure overload
(FIGS. 1B and C). In contrast, other stress responsive genes,
such as those encodingANF and BNP,were strongly induced
in miR-208 mutant animals (FIG. 1B), demonstrating that
miR-208 is dedicated specifically to the control of B-MHC
expression, which can be uncoupled from otherfacets of the
cardiac stress response.
Example 2
Knockdown of miR-208 Phenocopies miR-208
Knockout Animals in Responseto Stress
To examinethe specificity of the effect of the absence of
miR-208 on the cardiac stress response, animals were
injected intravenously daily with either an antagomir having
a sequence complementary to the mature miR-208 sequence
(anti 208; SEQ ID NO: 16) or a mismatched sequence (mm;
SEQ ID NO:17). All nucleosides were 2'-OMe modified, and
the 5' terminal two and 3' terminal four bases contained a
phosphorothioate internucleoside. Cholesterol was attached
to the 3' end of the passengerstrand through a hydroxyproli-
nol linker (FIG. 2A). Realtime PCR analysis of hearts of
animals injected with the miR-208 antagomir two months
after treatment showed efficient knockdown of miR-208
(FIG. 2B).
Totest the effect ofin vivo miR-208 downregulation on the
cardiac stress response, animals receiving either the anti-
miR-208 antagomir or the mismatched control were subject
to a sham procedureor a thoracic aortic banding procedure to
induce pressure overload. Animals that were treated with the
mismatched control exhibited a typical stress response with
upregulation of B-MHCas well as other stress genes (ANF
and BNP). In contrast, animals that were treated with the
anti-miR-208 antagomir failed to show an upregulation of
B-MHC in response to the stress stimulus. However, an
increase in expression of the other stress genes (ANF and
BNP) wasobserved (FIG.2C). Thestress response ofanimals
treated with the anti-miR-208 antagomir was remarkably
similar to that of miR-208 knockout animals suggesting that
miR-208 plays a critical role in the regulation of B-MHC
expression in responsetostress.
Example 3
MiR-208 is Required for Expression of miR-499
To further explore the mechanism ofaction ofmiR-208 in
the heart, the inventors defined the miRNA expression pat-
terns in hearts from wild type and miR-208 knockout mice by
microarray analysis. Among several miRNAsthat were up-
and down-regulated in miR-208 knockouthearts, the inven-
tors discovered that miR-499 was highly abundantin normal
hearts, but was not expressed above backgroundlevels in
miR-208 knockout animals. These findings were confirmed
by Northern blot (FIG. 3). Analysis ofthe genomic location of
the miR-499 gene showed it to be contained within the 20”
intron of the Myh7b gene, a homolog of the a-MHCgene.
MiR-208 appears to regulate Myh7b and thereby miR-499
expression at the level of transcription since RT-PCR for
Myh7b indicates that the mRNA of the host gene is dose-
dependently abrogated in the absence of miR-208 (FIG.3).
The Myh7b gene is conserved in vertebrates and is
expressed solely in the heart and slow skeletal muscle (e.g.
soleus) (FIG. 4A). Similarly, miR-499 has the same expres-
sion pattern as its host gene as confirmed by real-time PCR
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analysis (FIG. 4A & B). In situ hybridization using a probe
directed against the 3' end of the Myh7b gene, indicated that
this myosin (and miR-499) was expressed in heart as early as
E10.5 (FIG. 4C). Later during embryogenesis, Myh7b/miR-
499 is also expressed in the somites. These data indicate that
miR-208 is required to drive an additional myosin, Myh7b,
which gives rise to related miR-499. In addition, miR-499 is
down-regulated during cardiac hypertrophy.
To further explore the role of miR-499 in pathological
cardiac hypertrophy and regulation of muscle contractility,
miR-499 knockout animals were generated. Genetic deletion
of miR-499 had no effect on expression of its host gene,
Myh7b (FIG. 5A). Western blot analysis ofhearts from miR-
499 mutant and wild-type animals for both a- and B-MHC
showedthat deletion of miR-499 does not affect the expres-
sion of either geneat the protein level (FIG. 5B). To examine
whether miR-499 had an effect on B-MHCregulation, wild-
type and miR-499 knockout animals received propylthiou-
racil (PTU), which induces hypothyroidism and upregulates
B-MHC. Both wild-type and miR-499 knockout animals
exhibited a decrease in a-MHCandan increase in B-MHCin
response to PTU (FIG. 5C). Surprisingly, unlike miR-208,
miR-499 is not required for the regulation of expression of
either a- or B-MHC.
Example 4
Dual Targeting of miR-208 and miR-499
MiR-208regulates the expression ofmiR-499 as shown by
the dose-dependent decrease in miR-499 expression in miR-
208 heterozygote and miR-208 knockout animals (FIG. 3 and
Example 3). To further elucidate the interaction between
miR-208 and miR-499, wild-type animals were injected
intravenously with saline or one of four doses (20 mg/kg, 40
mg/kg, 80 mg/kg, and 160 mg/kg) of a synthetic oligonucle-
otide (e.g. an antagomir) having a sequence complementary
to the mature miR-208 sequence(anti-miR-208; SEQ ID NO:
16). Northern analysis ofheart tissue three daysafter tail vein
injection revealed a dose-dependent decrease in the expres-
sion of mature miR-208, while leaving the expression of the
pre-miR-208 intact (FIG. 6A). However, unlikein the genetic
deletion model, the expression of miR-499 remained
unchanged. In addition, expression levels of B-MHC were
also unaffected three days after injection of an anti-miR-208
antagomir (data not shown).
In a secondseries of experiments, wild-type animals were
injected intravenously either with a single dose of anti-miR-
208 (80 mg/kg), two sequential doses (80 mg/kg) of anti-
miR-208 on two consecutive days, or two sequential doses
(80 mg/kg) ofa mismatchedcontrol oligonucleotide (SEQ ID
NO:17) on two consecutive days. Northern analysis of car-
diac tissue two monthsafter treatment showedthat both miR-
208 and miR-499 expression was reduced in animals treated
with anti-miR-208 (FIG. 6B). Realtime PCR analysis con-
firmed these results (FIG. 6C). In addition, a decrease in
expression ofmiR-208b, which is encoded within anintron of
B-MHCandco-expressed with B-MHC,wasalso observed.
Realtime PCR analysis for the corresponding host myosin
genes revealed that knockdown of miR-208 does not affect
the expression of a-MHC, but induces a decrease in the
expression of B-MHC and Myh7b (FIG. 6C). A decrease in
B-MHCprotein was also observedtwo monthsafter treatment
with anti-miR-208 (FIG. 6D). These results indicate miR-208
regulation ofmiR-499 and B-MHCexpression occurs after a
delay suggesting that miR-208 is upstream of miR-499,
whichinturnis upstream of B-MHC.Thus, both miR-208 and
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miR-499 need to be downregulated to obtain an expedited
reduction of B-MHC expression. MiR-208 downregulation
alone leads to an eventual decrease in miR-499 expression,
which in turn induces a decrease in B-MHC expression. To
obtain a more immediate effect on B-MHC expression, both
miR-499 and miR-208 can be targeted for downregulation.
To examine the combined effect of downregulating both
miR-208 and miR-499, miR-499 knockout animals were
administered anti-miR-208 oligonucleotides prior to receiv-
ing propylthiouracil (PTU), an inducer of }-MHC expres-
sion. Similar to previous results, PTU induced a decrease in
a-MHC expression and an increase in B-MHC/miR-208b
expression (miR-208b is co-expressed with B-MHC)in both
wild-type and miR-499 knockout animals in the absence of
treatment with anti-miR-208 oligonucleotides (FIG. 7A, B).
Such effects are characteristic of the cardiac stress response.
In contrast, northern and realtime PCR analysis of cardiac
tissue from miR-499 knockout animals treated with anti-
miR-208 oligonucleotides two weeksafter treatment showed
that an increase in B-MHC/miR-208b expression in response
to PTU wasnot observed (FIG. 7A,B). The response of the
miR-499 knockout animals treated with anti-miR-208
resembled the response ofmiR-208 knockout animals (FIG.
7B). These results suggest that efficient and rapid downregu-
lation of B-MHCcan be achieved bytargeting both miR-208
and miR-499. The dosage of anti-miR-208 oligonucleotides
that were administered to the animals produced a 60% reduc-
tion in miR-208 expression. This percentage reduction was
sufficient to suppress the induction of B-MHC by PTU in the
absence of miR-499 (FIG. 7B). These findings indicate that
reduction of both miR-499 and miR-208 maybean efficient
therapeutic strategy for the treatment of cardiac disorders,
such as pathological cardiac hypertrophy and heart failure.
Example 5
Knockdown of miR-208 and miR-499 Inhibits the
Cardiac Stress Response
To further assess the therapeutic value of targeting miR-
208 and miR-499 for treating cardiac disorders, mice are
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injected intravenously with an antisense oligonucleotide hav-
ing a sequence complementary to the mature miR-208a
sequence (anti-208), an antisense oligonucleotide having a
sequence complementary to the mature miR-499 sequence
(anti-499), or both anti-208 and anti-499 oligonucleotide
sequences. Both anti-208 and anti-499 contain a combination
of locked nucleic acids (LNA) and deoxyribonucleic acids
(DNA)linked by phosphorothioate internucleoside linkages.
Realtime PCR analysis of hearts of animals injected with the
antisense oligonucleotides three weeks up to two months
after treatment is used to assess knockdown of miR-208 and
miR-499.
To test the effect of in vivo miR-208 and miR-499 down-
regulation on the cardiac stress response, animals receiving
the anti-208, anti-499, or both the anti-208 and anti-499 oli-
gos are subject to a sham procedure or a thoracic aortic
banding procedure to induce pressure overload. Animals that
are untreated are expected to exhibit a typical stress response
with upregulation of }-MHC as well as other stress genes
(ANF and BNP). In contrast, animals that are treated with
both anti-208 and anti-499 are expected to exhibit a reduced
upregulation of 8-MHCinresponseto the stress stimulus that
is more pronounced than animals receiving either antisense
oligo alone.
All publications, patents and patent applications discussed
and cited herein are incorporated herein by reference in their
entireties. It is understood that the disclosed invention is not
limited to the particular methodology, protocols and materi-
als described as these can vary. It is also understoodthat the
terminology used herein is for the purposes of describing
particular embodiments only and is not intended to limit the
scope ofthe present invention which will be limited only by
the appended claims.
Those skilled in the art will recognize, or be able to ascer-
tain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention
described herein. Such equivalents are intended to be encom-
passed by the following claims.
 
SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 19
<210> SEQ ID NO 1
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 1
acgggegage ttttggeceg ggttatacct gatgetcacg tataagacga gcaaaaagcet
tgttggtcag a
<210>
<211>
<212>
<213>
SEQ ID NO 2
LENGTH: 71
TYPE: DNA
ORGANISM: Mus sp.
<400> SEQUENCE: 2
acgggtgage ttttggeceg ggttatacct gactctcacg tataagacga gcaaaaagcet
tgttggtcag a
<210> SEQ ID NO 3
60
71
60
71
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<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 3
acgggtgage ttttggceccg ggttatacct gactctcacg tataagacga gcaaaaaget
tgttggtcag a
<210> SEQ ID NO 4
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Canis sp.
<400> SEQUENCE: 4
acgcatgage ttttggctcg ggttatacct gatgetcacg tataagacga gcaaaaaget
tgttggtcag a
<210>
<211>
<212>
<213>
<220>
<223>
<400>
SEQ ID NO 5
LENGTH: 22
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: mature miR-208
SEQUENCE: 5
auaagacgag caaaaagecuu gu
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 6
LENGTH: 76
TYPE: DNA
ORGANISM: Mus sp.
SEQUENCE: 6
tecetgtgte ttgggtggge agetgttaag acttgcagtg atgtttaget cctctgcatg
tgaacatcac agcaag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 7
LENGTH: 74
TYPE: DNA
ORGANISM: Rattus sp.
SEQUENCE: 7
tecetgtctt gggtgggcag ctgttaagac ttgcagtgat gtttagetce tctccatgtg
aacatcacag caag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 8
LENGTH: 76
TYPE: DNA
ORGANISM: Homo sapiens
SEQUENCE: 8
cecetgtgee ttgggeggge ggctgttaag acttgcagtg atgtttaact cctctccacg
tgaacatcac agcaag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 9
LENGTH: 76
TYPE: DNA
ORGANISM: Canis sp.
SEQUENCE: 9
cecttgcace ctgggeggge ggecgttaag acttgcagtg atgtttaact cctctccacg
60
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tgaacatcac agcaag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 10
LENGTH: 76
TYPE: DNA
ORGANISM: Didelphis sp.
SEQUENCE: 10
cecetgecte ceeggeggge agetgttaag acttgcagtg atgtttaatt cttctctatg
tgaacatcac aacaag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 11
LENGTH: 62
TYPE: DNA
ORGANISM: Gallus sp.
SEQUENCE: 11
ggageggeag ttaagacttg tagtgatgtt tagataatgt attacatgga catcacttta
ag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 12
LENGTH: 68
TYPE: DNA
ORGANISM: Xenopus tropicalis
SEQUENCE: 12
gtcttagega ggcagttaag acttgcagtg atgtttagtt aaaatctttt catgaacatc
actttaag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 13
LENGTH: 79
TYPE: RNA
ORGANISM: Mus sp.
SEQUENCE: 13
gggugggeag cuguuaagac uugcagugau guuuagcuce ucugcaugug aacaucacag
caagucugug cugcugecu
<210>
<211>
<212>
<213>
<220>
<223>
<400>
SEQ ID NO 14
LENGTH: 21
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: mature miR-499
SEQUENCE: 14
uuaagacuug cagugauguu u
<210>
<211>
<212>
<213>
<220>
<223>
<400>
SEQ ID NO 15
LENGTH: 22
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: miR-208 antagomir
SEQUENCE: 15
acaagcuuuu ugeucgucuu au
<210>
<211>
<212>
<213>
<220>
SEQ ID NO 16
LENGTH: 22
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
76
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-continued
<223> OTHER INFORMATION: antimiR-208 oligonucleotide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1).. (22)
<223> OTHER INFORMATION: May be 2'-OMe modified oligonucleosides
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1).. (2)
<223> OTHER INFORMATION: May contain phosphorothioate internucleoside
linkages
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (19). .(22)
<223> OTHER INFORMATION: May contain phosphorothioate internucleoside
linkages
<400> SEQUENCE: 16
acaagcuuuu ugcucgucuu au 22
<210> SEQ ID NO 17
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: mismatch miR-208 oligonucleotide
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1).. (22)
<223> OTHER INFORMATION: May be 2'-OMe modified oligonucleosides
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1).. (2)
<223> OTHER INFORMATION: May contain phosphorothioate internucleoside
linkages
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (19). .(22)
<223> OTHER INFORMATION: May contain phosphorothioate internucleoside
linkages
<400> SEQUENCE: 17
accagcuuug ugcucguaug au 22
<210> SEQ ID NO 18
<211> LENGTH: 43
<212> TYPE: DNA
<213> ORGANISM: Unknown
<220> FEATURE:
<223> OTHER INFORMATION: pre-miR-208b
<400> SEQUENCE: 18
tttctgatce gaatataaga cgaacaaaag gtttgtctga ggg 43
<210> SEQ ID NO 19
<211> LENGTH: 22
<212> TYPE: RNA
<213> ORGANISM: Unknown
<220> FEATURE:
<223> OTHER INFORMATION: mature miR-208b
<400> SEQUENCE: 19
auaagacgaa caaaagguuu gu 22
 
60The invention claimedis:
1. A method of reducing a cardiac stress response in a
subject in need thereof comprising administering to the sub-
ject:
an inhibitor ofmiR-208a or miR-208b, wherein the inhibi- 65
tor ofmiR-208a or miR-208b is an antisense oligonucle-
otide comprising a sequencethat is sufficiently comple-
mentary to a miR-208a or miR-208b sequence to
hybridize to the miR-208a or miR-208b sequence under
physiological conditions and inhibit the expression or
activity of miR-208a or miR-208bin heart cells of said
subject; and
an inhibitor ofmiR-499, wherein the inhibitor ofmiR-499
is an antisense oligonucleotide comprising a sequence
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that is sufficiently complementary to a miR-499
sequence to hybridize to the miR-499 sequence under
physiological conditions and inhibit the expression or
activity of miR-499 in heart cells of said subject, and
wherein the cardiac stress response is reduced in the sub-
ject withintwo weeksofadministration ofthe inhibitors.
2. The method of claim 1, wherein the inhibitor of miR-
208a or miR-208b and the inhibitor of miR-499 are co-ad-
ministered.
3. The method of claim 2, wherein the inhibitor of miR-
208a or miR-208b andthe inhibitor ofmiR-499 are encoded
by an expression vector.
4. The method of claim 3, wherein the inhibitor of miR-
208a or miR-208b andthe inhibitor ofmiR-499 are encoded
by the same expression vector.
5. The method of claim 1, wherein the inhibitor of miR-
208a or miR-208b and the inhibitor ofmiR-499 are adminis-
tered sequentially.
6. The method of claim 5, wherein the inhibitor of miR-
208a or miR-208b is administered prior to the inhibitor of
miR-499.
7. The method ofclaim 5, wherein the inhibitor ofmiR-499
is administered prior to the inhibitor of miR-208a or miR-
208b.
8. The method of claim 5, wherein the inhibitor of miR-
208a or miR-208b and the inhibitor ofmiR-499 are adminis-
tered at least 24 hoursapart.
9. The method of claim 1, wherein the inhibitor of miR-
208a or miR-208b and the inhibitor ofmiR-499 are adminis-
tered at a dosage of about 1 mg/kg to about 200 mg/kg.
10. The method of claim 1, wherein the expression or
activity ofmiR-208a or miR-208b and miR-499 is reduced by
greater than 60 percent in the heart cells of the subject fol-
lowing administration of the inhibitors.
11. The method of claim 1, wherein the cardiac stress
response includes cardiomyocyte hypertrophy, fibrosis ofthe
heart, reduced expression ofa-MHCinthe heart cells, and/or
increased expression of B-MHCin the heart cells of said
subject.
12. The method of claim 1, wherein the inhibitor of miR-
208a or miR-208bis an antisense oligonucleotide comprising
asequencethatis at least 85% complementary to SEQ ID NO:
5 or SEQ ID NO:19.
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13. The methodof claim 1, wherein the inhibitor of miR-
208a or miR-208bis an antisense oligonucleotide comprising
asequencethatis at least 95% complementary to SEQ ID NO:
5 or SEQ ID NO:19.
14. The methodof claim 1, wherein the inhibitor of miR-
208a or miR-208bis an antisense oligonucleotide comprising
a sequencethat is 100% complementary to SEQ ID NO:5 or
SEQ ID NO:19.
15. The methodof claim 1, wherein the inhibitor of miR-
499 is an antisense oligonucleotide comprising a sequence
that is at least 85% complementary to SEQ ID NO:14.
16. The method of claim 1, wherein the inhibitor of miR-
499 is an antisense oligonucleotide comprising a sequence
that is at least 95% complementary to SEQ ID NO:14.
17. The methodof claim 1, wherein the inhibitor of miR-
499 is an antisense oligonucleotide comprising a sequence
that is 100% complementary to SEQ ID NO: 14.
18. The method ofclaim 1, wherein the miR-208a or miR-
208b antisense oligonucleotide and the miR-499 antisense
oligonucleotide comprise at least one sugar and/or backbone
modification.
19. The method ofclaim 18, wherein saidat least one sugar
modification is a bicyclic sugar nucleoside modification,
2'-O-alkyl modification, or 2'-fluoro modification.
20. The method of claim 19, wherein said bicyclic sugar
nucleoside modification is a locked nucleic acid.
21. The method of claim 18, wherein said at least one
backbone modification is a phosphorothioate linkage.
22. The methodofclaim 1, wherein the miR-208a or miR-
208b antisense oligonucleotide and the miR-499 antisense
oligonucleotide are about8 to about 18 nucleotides in length.
23. The methodofclaim 1, wherein the miR-208a or miR-
208b antisense oligonucleotide and the miR-499 antisense
oligonucleotide are about 12 to about 16 nucleotides in
length.
24. The method of claim 1, wherein the inhibitor of miR-
208a or miR-208b andthe inhibitor ofmiR-499are present in
separate compositions.
25. The method of claim 1, wherein the inhibitor of miR-
208a or miR-208b andthe inhibitor ofmiR-499are present in
the same composition.
26. The method ofclaim 1, wherein the subjectis at risk for
developing pathologic cardiac hypertrophy, heart failure, or
myocardial infarction.
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